Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.44 |
| ▸ | KDM4A | O75164 | 2/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.44 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.44 |
| ▸ | TET3 | O43151 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31222658 | 1.00 | CYP1A2 (0.48) | CYP1A2CYP2C19TET2KDM4AKDM4C | |
| SCHEMBL30141848 | 1.00 | CYP1A2 (0.48) | CYP1A2CYP2C19TET2KDM4AKDM4C | |
| SCHEMBL10305355 | 0.94 | CYP1A2 (0.43) | CYP1A2CYP2C19TET2KDM4AKDM4C | |
| SCHEMBL14547871 | 0.94 | CYP1A2 (0.43) | CYP1A2CYP2C19TET2KDM4AKDM4C | |
| SCHEMBL10830109 | 0.91 | CYP1A2 (0.45) | CYP1A2CYP2C19TET2KDM4AKDM4C | |
| SCHEMBL18752953 | 0.90 | CYP1A2 (0.45) | CYP1A2CYP2C19TET2KDM4AKDM4C | |
| SCHEMBL22821452 | 0.90 | CYP1A2 (0.45) | CYP1A2CYP2C19TET2KDM4AKDM4C | |
| SCHEMBL28297074 | 0.90 | CYP1A2 (0.43) | CYP1A2CYP2C19TET2KDM4AKDM4C | |
| SCHEMBL25137272 | 0.89 | ALB (0.43) | CYP1A2CYP2C19TET2KDM4AKDM4C | |
| SCHEMBL21447656 | 0.89 | ALB (0.43) | CYP1A2CYP2C19TET2KDM4AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4610269-A1 | UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE | 3B Pharmaceuticals GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| US-8926945-B2 | Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium | GUERBET (FR) | 2015-01-06 | — | — | US | disclosed |
| US-8540966-B2 | Contrast agents endowed with high relaxivity | BRACCO IMAGING S.P.A. (IT) | 2013-09-24 | — | — | US | disclosed |
| US-8367039-B2 | Compounds for the diagnosis of diseases associated with VCAM expression | GUERBET (FR) | 2013-02-05 | — | — | US | disclosed |
| US-8367039-B2 | Compounds for the diagnosis of diseases associated with VCAM expression | GUERBET (FR) | 2013-02-05 | — | — | US | disclosed |
| US-8114863-B2 | Compounds comprising short aminoalcohol chains and metal complexes for medical imaging | GUERBET (FR) | 2012-02-14 | — | — | US | disclosed |
| US-8114863-B2 | Compounds comprising short aminoalcohol chains and metal complexes for medical imaging | GUERBET (FR) | 2012-02-14 | — | — | US | disclosed |
| US-20120009124-A1 | USE OF BUFFERS FOR RADIONUCLIDE COMPLEXATION | GUERBET (FR) | 2012-01-12 | — | — | US | disclosed |
| US-20120009124-A1 | USE OF BUFFERS FOR RADIONUCLIDE COMPLEXATION | GUERBET (FR) | 2012-01-12 | — | — | US | disclosed |
| US-20110256067-A1 | Contrast agents endowed with high relaxivity | BRACCO IMAGING SPA (IT) | 2011-10-20 | — | — | US | disclosed |
| US-20090169479-A1 | Compounds Comprising Short Aminoalcohol Chains and Metal Complexes for Medical Imgaing | GUERBET (FR) | 2009-07-02 | — | — | US | disclosed |
| EP-1765812-B1 | CONTRAST AGENTS ENDOWED WITH HIGH RELAXIVITY FOR USE IN MAGNETIC RESONANCE IMAGING (MRI) WHICH CONTAIN A CHELATING MOIETY WITH POLYHYDROXYLATED SUBSTITUENTS | BRACCO IMAGING SPA (IT) | 2009-04-29 | — | — | EP | disclosed |
| EP-1786475-B1 | 1,4-BIS(CARBOXYMETHYL)-6-[BIS(CARBOXYMETHYL)AMINO]-6-METHYL-PERHYDRO-1,4-DIAZEPINE (AAZTA) DERIVATIVES AS LIGANDS IN HIGH RELAXIVITY CONTRAST AGENTS FOR USE IN MAGNETIC RESONANCE IMAGING (MRI) | BRACCO IMAGING SPA (IT) | 2009-04-29 | — | — | EP | disclosed |
| US-20070258905-A1 | Contrast Agents Endowed with High Relaxivity for Use in Magnetic Resonance Imaging (Mri) Which Contain a Chelating Moiety with Polyhydroxylated Substituents | BRACCO IMAGING SPA (IT) | 2007-11-08 | — | — | US | disclosed |
| US-20070258905-A1 | Contrast Agents Endowed with High Relaxivity for Use in Magnetic Resonance Imaging (Mri) Which Contain a Chelating Moiety with Polyhydroxylated Substituents | BRACCO IMAGING SPA (IT) | 2007-11-08 | — | — | US | disclosed |
| US-20070098643-A1 | Oligomers of gadolinium chelates, their applicationascontrast products in magnetic resonance imaging and their synthesis intermediates | GUERBET (FR) | 2007-05-03 | — | — | US | disclosed |
| EP-0661279-B1 | Polyaminated ligands, metal complexes, process for their preparation and diagnostic and therapeutic applications | GUERBET SA (FR) | 2001-03-07 | — | — | EP | disclosed |
| US-5919432-A | Polyaminated ligands and metal complexes thereof | GUERBET S.A. (FR) | 1999-07-06 | — | — | US | disclosed |
| US-5712389-A | Polyaminated ligands and metal complexes thereof | GUERBET S.A. (FR) | 1998-01-27 | — | — | US | disclosed |
| EP-0661279-A1 | Polyaminated ligands, metal complexes, process for their preparation and diagnostic and therapeutic applications | GUERBET S.A. (FR) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110256067-A1 | Contrast agents endowed with high relaxivity | SLC40A1, SLC67A1, SLC19A1 | CYP1A2 2312/4885CYP2C19 4045/4885TET2 3522/4885 |
| US-20120009124-A1 | USE OF BUFFERS FOR RADIONUCLIDE COMPLEXATION | CA5B, CA3, CA1 | CYP1A2 3254/4885CYP2C19 1785/4885TET2 3922/4885 |
| US-20090169479-A1 | Compounds Comprising Short Aminoalcohol Chains and Metal Complexes for Medical Imgaing | AVPR2, NR2E3, INSR | CYP1A2 1370/4885CYP2C19 2714/4885TET2 3485/4885 |
| US-20070098643-A1 | Oligomers of gadolinium chelates, their applicationascontrast products in magnetic resonance imaging and their synthesis intermediates | MGAT2, MGAT1, MGAT3 | CYP1A2 4652/4885CYP2C19 4876/4885TET2 2353/4885 |
| US-20070258905-A1 | Contrast Agents Endowed with High Relaxivity for Use in Magnetic Resonance Imaging (Mri) Which Contain a Chelating Moiety with Polyhydroxylated Substituents | RXFP1, SLC5A7, SLC40A1 | CYP1A2 4225/4885CYP2C19 4771/4885TET2 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.